BioSpace News Archive

Verge Genomics announced that it has entered into a collaboration with the Pritzker Neuropsychiatric Disorders Research Consortium to further the company’s cutting-edge research on schizophrenia.

BeyondSpring Inc. announced that the Company and Professor Kathryn M. Eisenmann of the University of Toledo College of Medicine presented a poster on the potent efficacy of plinabulin in a derived patient model of glioblastoma, a disease of high unmet need at the 2023 AACR Special Conference in Cancer Research: Brain Cancer on Oct 20th, 2023 at Minneapolis, MN.

AceLink Therapeutics, Inc., a clinical-stage biopharmaceutical company developing the next generation of oral substrate reduction therapies (SRTs), announced today that the first patient has been dosed with AL01211 in its Phase 2 trial in China in patients with Fabry disease.

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its third quarter 2023 financial results after market close on Tuesday, November 7, 2023.

Twist Bioscience Corporation, a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, announced the launch of Twist Full Length Unique Dual Index Adapters to enable PCR-free whole genome sequencing and multiplexing at scale.

DNAnexus, Inc., the premier precision health data cloud provider, today announced the speaker lineup for its presentations at the American Society of Human Genetics (ASHG) Annual Meeting 2023, which is being held in Washington, D.C., this week.

Apollomics Inc. today announced the addition of two new cohorts in its ongoing global multi-cohort Phase 2 SPARTA study (NCT03175224), which is evaluating vebreltinib (APL-101) in patients with non-small cell lung cancer (NSCLC) and other solid tumors.

Axsome Therapeutics, Inc. announced that Herriot Tabuteau, MD, Axsome’s Chief Executive Officer, will participate in two upcoming investor conferences in early November.

Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that data for its novel, potential first-in-class investigational bispecific antibody, ivonescimab, will be presented at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in San Diego, CA.

Microbot Medical Inc., developer of the innovative LIBERTY® Robotic Surgical System, announces additional updates regarding positive outcomes of its previously announced pivotal pre-clinical study using the LIBERTY Robotic Surgical System.